Cancer Treatment in the Era of COVID-19 | Chapter 2 | Current Practice in Medical Science Vol. 2

The COVID-19 outbreak negatively impacted India's healthcare system, causing delays in the provision of preventative, therapeutic, and supportive treatment to cancer patients. Patients with cancer are particularly vulnerable to the severe type of COVID-19. The relationship between the two disorders is established by the angiotensin-converting enzyme 2 (ACE2) receptor, transmembrane protease serine 2 (TMPRSS2), immunological response, and inflammation. Cancer patients had a 76 percent greater COVID-19 severity. The COVID-19 outbreak's quick spread and the unusual, nearly total global shutdown that followed have exposed the gaps in health systems. India built shared decision-making procedures and open electronic communication channels despite the fact that face-to-face meetings are not possible. During the epidemic, hospitals in India created a series of webinars that were accessible through the National Cancer Grid to disseminate best practises and recommendations for cancer treatment. India fared very well in efficiently controlling COVID-19 and cancer patients.

Author(s) Details:

Sunder Singh,

Department of Radiation Oncology, Pt. BDS PGIMS, Rohtak, Haryana, India.

Abhishek Soni,

Department of Radiation Oncology, Pt. BDS PGIMS, Rohtak, Haryana, India.

Vivek Kaushal,

Department of Radiation Oncology, Pt. BDS PGIMS, Rohtak, Haryana, India.

Ashok Chauhan,

Department of Radiation Oncology, Pt. BDS PGIMS, Rohtak, Haryana, India.

Please see the link here: https://stm.bookpi.org/CPMS-V2/article/view/7341